European Schizophrenia Drugs Market Size, Industry Trends, Share and Forecast 2020-2026
The European schizophrenia drug market is projected to grow at a significant CAGR of around 2.5% during the forecast period (2020-2026). The availability of considerable resources for mental health and a sophisticated healthcare system are other key factors that are expected to promote the growth of the market. In the UK, Mental Health First Aid (MHFA) England, a social organization that offers expert guidance and training to support mental health, estimated in 2019 that nearly one in four people face mental health issues each year and are responsible for 72 million working days lost and costs $45.5 billion each year. Therefore, a significant market is estimated in Europe for schizophrenia drugs.
To
Request a Sample of our Report on European
Schizophrenia Drugs Market:
https://www.omrglobal.com/request-sample/european-schizophrenia-drugs-market
Further,
according to the WHO, almost 83 million people are affected annually by mental disorders
among the adult population of Europe (aged 18-65), where female rates are
higher than males. This involves the high demand for products which can bring
down the level of schizophrenia among people. According to the Institute for
Health Metrics and Evaluation (IHME), the EU spent an average of $22 per capita
on mental health programs and services in 2016. Nearly all the countries in the
European region had a stand-alone or integrated mental health policy or plan.
This can be considered as another factor for the substantial growth of the
market in the region.
Key questions addressed by the report
·
What is the market growth rate during the forecast
period?
·
Which segment/region dominates the market in the
base year?
·
Which segment/region will project the fastest
growth in the market during the forecast period?
·
How COVID-19 will impact the market growth in 2020
and coming years?
·
Recovery Timeline
·
Deviation from pre-COVID-19
·
Most affected region/segment
·
Recommendations
·
Who is the leader in the market?
·
How players are addressing challenges to sustain
growth?
·
Where is the investment opportunity?
(Get 15% Discount on Buying this Report)
A full Report of European Schizophrenia Drugs Market is Available at: https://www.omrglobal.com/industry-reports/european-schizophrenia-drugs-market
European Schizophrenia Drugs Market – Segmentation
By Therapeutic Class
·
Second Generation Antipsychotics
·
Third Generation Antipsychotics
·
Others (First Generation Antipsychotics)
By Treatment
·
Oral
·
Injectables
European Schizophrenia Drugs Market – Segmentation
by Geography
·
UK
·
Germany
·
Italy
·
France
·
Spain
Rest of Europe
Company Profiles
·
Alkermes PLC
·
Allergan PLC
·
AstraZeneca PLC
·
Biogen, Inc.
·
Eli Lilly and Co.
·
H. Lundbeck A/S
·
Johnson & Johnson Services, Inc.
·
Lupin,Ltd.
·
Merck & Co., Inc.
·
Otsuka Pharmaceutical Co., Ltd.
·
Pfizer, Inc.
·
Teva Pharmaceutical Industries Ltd.
Reasons
to buy from us –
1.
We cover more than 15 major industries, further segmented into more than 90
sectors.
2.
More than 120 countries are for analysis.
3.
Over 100+ paid data sources mined for investigation.
4.
Our expert research analysts answer all your questions before and after
purchasing your report.
For More
Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-schizophrenia-drugs-market
About Orion
Market Research
Orion Market Research (OMR) is a market
research and consulting company known for its crisp and concise reports. The
company is equipped with an experienced team of analysts and consultants. OMR
offers quality syndicated research reports, customized research reports,
consulting and other research-based services.
Media Contact:
Company Name: Orion
Market Research
Contact Person: Mr.
Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment